Two Sigma Advisers LP boosted its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 151.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,600 shares of the health services provider's stock after purchasing an additional 8,200 shares during the period. Two Sigma Advisers LP's holdings in Amedisys were worth $1,235,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in AMED. Blue Trust Inc. grew its stake in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after acquiring an additional 124 shares during the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Amedisys in the fourth quarter valued at approximately $55,000. Vestcor Inc acquired a new position in shares of Amedisys in the fourth quarter valued at approximately $73,000. Venturi Wealth Management LLC lifted its stake in shares of Amedisys by 397.4% during the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock valued at $89,000 after buying an additional 779 shares during the period. Finally, Covestor Ltd boosted its position in Amedisys by 48.8% during the fourth quarter. Covestor Ltd now owns 1,037 shares of the health services provider's stock worth $94,000 after acquiring an additional 340 shares during the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.
Analyst Upgrades and Downgrades
AMED has been the subject of a number of recent analyst reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a research report on Wednesday, April 16th. Stephens restated an "equal weight" rating and issued a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Finally, Wall Street Zen lowered shares of Amedisys from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 24th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $100.75.
Get Our Latest Analysis on AMED
Amedisys Trading Up 0.1%
Shares of AMED traded up $0.09 during trading hours on Wednesday, hitting $94.58. The stock had a trading volume of 25,383 shares, compared to its average volume of 408,151. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The firm has a market cap of $3.10 billion, a P/E ratio of 37.53, a P/E/G ratio of 1.78 and a beta of 0.96. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The company's fifty day simple moving average is $93.55 and its 200 day simple moving average is $91.64.
Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. During the same period last year, the business posted $1.03 EPS. The company's quarterly revenue was up 4.1% compared to the same quarter last year. Equities research analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.
About Amedisys
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Read More
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
